MDXX class molecules

PharmAla Biotech Holdings Inc. (OTC:MDXXF), a Toronto-based biotechnology company, has secured a contract to supply MDMA for a clinical trial conducted by Johns Hopkins Medicine. This marks a significant milestone for the company as it expands its role in providing MDMA and its novel derivatives...

The U.S. Patent and Trademark Office (USPTO) has granted PharmAla Biotech Holdings (OTC:MDXXF) a national patent covering the composition of matter of its lead novel compound, ALA-002.   The Novel Chemical Entity (NCE) is among the group of MDXX-class molecules under development by the biotech....

Terran Biosciences, the NY-based biotech platform that develops transformational therapeutics announced the publication of four international PCT patent applications covering novel compounds and potentially improved versions of the empathogens methylone (also called bk-MDMA or MDMC...

PharmAla Biotech Holdings Inc, the biotech company producing MDXX class molecules has released a large-scale batch of its proprietary MDMA API, “Laneo,” becoming the first publicly-traded venture to produce the drug within Good Manufacturing Processes (GMP) in such a major...